CRXM — Gene Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.49m
Annual income statement for Gene Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2016 December 31st | 2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.84 | 2.08 | 0.513 | 0.837 | 1.19 |
| Operating Profit | -2.84 | -2.08 | -0.513 | -0.837 | -1.19 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.01 | -2.1 | -0.553 | 0.779 | -0.652 |
| Net Income After Taxes | -3.01 | -2.1 | -0.553 | 0.779 | -0.652 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.92 | -1.89 | -0.435 | 0.867 | -0.518 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.7 | -1.89 | -0.435 | 0.867 | -0.518 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.278 | -0.136 | -0.075 | 0.06 | -0.049 |